Welcome to the era of financial freedom, where human ingenuity is rewarded forever.
Probitect seals every song, story, image, style and discovery the moment it's made, with a hidden, blockchain-backed mark of origin. Fakes lose their power. And every use, remix, adaptation, and AI that learns from your work pays you back, for as long as it's used.
"NFT" came to mean a speculative token that anyone could mint for anything, usually after the fact. ByteRun flips that. A Probitect seal is created at the source, by an authorized device, on behalf of a verified human or organization. It carries ownership, license terms and royalty routing with the work for its whole life.
To seal a work at creation with its maker's verified origin and terms. Also the seal itself.
Has no proof of origin. Treat it like an unsigned check: maybe real, never trusted.
The unbroken chain from creation to every reuse, remix, license and training run.
The micro-royalty paid to an originator each time their work is used.
ByteRun runs quietly on your computer, camera and phone. Nothing about how you create changes. Everything you make just leaves with proof attached.
A lightweight agent on your terminal, camera or DAW notices each new work as it's made: an image, a track, a manuscript, a dataset.
Your device's secure key signs a fingerprint of the content and your identity. An invisible watermark goes into the signal itself.
Only the fingerprint, ownership and license terms are written to a public blockchain as a smart contract, never the file itself, never the file. That gives the work a permanent, timestamped birth record anyone can check.
Licenses, citations, remixes and AI-training uses all trigger payment automatically. Even fractions of a cent add up when they're paid out at scale.
Point ByteRun at your studio folder, camera roll or repo. It watches, probitects and registers in the background. No marketplace, no minting fees, no crypto wallet to manage.
Today, a convincing fake clip of a CEO, politician or artist can move markets and reputations in minutes. With Probitect seals the question flips: you don't have to prove a clip is fake, because the real one comes with proof. Try the verifier below.
Every model is trained on human work. Probitect seals make that work countable. Each time a probitected work goes into a training set, gets retrieved, or is cited in an answer, a micro-royalty flows back to the person who made it. It's a new, global source of income from human creativity.
Illustrative only. Real rates will be set by the market and by licensing agreements.
We're signing publishing houses and children's bookstores to the Probitect network. Each title's rights are probitected once and written into a smart contract on the blockchain. After that, the book can be licensed as an audiobook, an animated series, an app or an AI-narrated story, and the author, illustrator and publisher get paid automatically wherever it plays.
A visual signature, a director's camera language or a composer's sound takes a lifetime to build. Artists can register their style in the Probitect Style Registry. When someone prompts an AI with "in the style of…" a registered artist, a tiny payment is triggered on that project, routed through the same blockchain-backed watermark that marks the finished output.
Artists choose their terms: allow and get paid, require approval, or opt out entirely.
Both platforms run on the same Probitect protocol. One is built for individual creators. The other is built for the most expensive intellectual property on Earth: medicine.
For photographers, musicians, writers, filmmakers, designers and public figures. Everything you make is protected, provable and earning, without changing how you work.
For biotech and pharma. Research, compounds, protocols and data are probitected as licensable assets, so the investment keeps paying back long after the patent clock runs out.
A new drug can take $1B or more and over a decade to develop. Patents last about 20 years from filing, but much of that time is spent in trials, so the window for selling the drug exclusively is often only around 10 years. If a disease affects too few people, the math never works, and the research doesn't get funded. ByteRun Bio changes the math: probitect the IP, license it openly to any qualified producer worldwide, and collect a royalty from every dose for far longer.
Illustrative model, cumulative net return to originators and investors in $M by year after launch. Assumes about 10 years of exclusivity followed by a generic cliff, compared with open licensing from year 3 and royalties continuing to year 30. It's a concept, not a forecast.
Royalties keep flowing from licensed production well past the exclusivity cliff, so the investment has decades to pay back instead of a few years.
When payback can stretch over a longer period and reach more countries, a patient population once seen as "too small" can still attract capital.
Any qualified manufacturer can license the probitected IP and produce the therapy. More supply reaches more patients, and every dose sends a royalty back to the people who funded the research.
The goal goes beyond an app: an open standard where every photo, recording, text, dataset and discovery carries its origin by default, from cameras and phones to labs and AI models. It builds on emerging content-provenance work such as C2PA Content Credentials, and adds what's been missing: ownership, licensing and payment.
Terminal agent, Probitect spec draft, verifier, and concept platforms.
Creator cohort on Create. First biotech and rare-disease partners on Bio.
Probitecting built into cameras and phones, plus usage receipts from AI labs.
Governed by a consortium. Probitect becomes the default for human-made work.
Join the first creators, labs and investors building the Probitect standard.